Since Tepezza is a biologic drug, it can't have a generic version. This is because biologics are made from living cells and can't be replicated exactly. Instead, it's possible for biologic drugs to have biosimilar versions. Biosimilars are just as safe and effective as the original biologic but often cost less.

TEPEZZA reduces eye bulging and double vision. It also improves the signs and symptoms of Thyroid Eye Disease (TED), including eye pain, redness, and swelling. TEPEZZA is a prescription medicine used to treat TED. You should discuss the risks and benefits of using TEPEZZA with your doctor.

Each vial contains 500 milligrams (mg) of the active drug, teprotumumab. Your healthcare professional will use the powder in the vial to make a solution. Then, they'll give the Tepezza solution to you as an intravenous (IV) infusion. (With an IV infusion, the drug is given into your vein over a period of time.)

How many patients have been treated with TEPEZZA? Over 14,500 TED patients have been treated with TEPEZZA.

Intravenous Powder For Injection

The manufacturer has priced Tepezza at $14,900 to $16,301.09 per vial in the United States. Treatment requires up to eight infusions. Total Tepezza cost will depend on your treatment plan. Coverage for Tepezza varies depending on health insurance plans.

Intravenous Powder For Injection

An insulin-like growth factor-1 receptor inhibitor, Tepezza is claimed to be the first and only medicine to receive approval from the FDA to treat TED, a rare progressive, debilitating and potentially vision-threatening autoimmune disease. The FDA's approval was granted in January 2020.

New York: Luxturna, a medication against hereditary degeneration of the retina that can lead to total blindness, will be sold for $850,000 in the United States, making it one of the world's most expensive medical treatments.

A new gene therapy called Luxturna for blindness will cost $850,000, says Spark Therapeutics, the company that makes it. Patients will get help paying for it.

Patient's prescription cannot be paid in part or in full by any government-funded program including but not limited to: Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, Department of Defense (DOD), TRICARE, or any state, patient foundation, or other pharmaceutical program.

Clinical studies have shown that Tepezza (teprotumumab) works well to improve eye symptoms, such as eye bulging, double vision, and eye pain and redness.